Sequent Scientific is currently trading at Rs. 982.00, up by 12.50 points or 1.29 % from its previous closing of Rs. 969.50 on the BSE.
The scrip opened at Rs. 998.00 and has touched a high and low of Rs. 1015.00 and Rs. 972.00 respectively. So far 5554 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1120.00 on 22-Sep-2015 and a 52 week low of Rs. 391.15 on 24-Nov-2014.
Last one week high and low of the scrip stood at Rs. 1040.00 and Rs. 951.00 respectively. The current market cap of the company is Rs. 4159.94 crore.
The promoters holding in the company stood at 56.33 % while Institutions and Non-Institutions held 25.08 % and 18.59 % respectively.
SeQuent Scientific’s subsidiary Alivira Animal Health has completed acquisition of Animal Health Business of Lyka Exports. The acquisition of Lyka’s Animal Health Business, which was originally announced on August 27, 2015, includes all IPR, Sales/Marketing/Distribution network with related employees, business contracts, assets and liabilities. The acquired business will significantly boost Alivira's product profile in cattle and dairy segment coupled with a 250+ field force and Pan India presence. Consolidation with SeQuent will be effected from the third quarter of FY16.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
